Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine
S Meza-Perez, M Liu, A Silva-Sanchez, CD Morrow… - Cell Host & Microbe, 2024 - cell.com
Gut microbiota influence anti-tumor immunity, often by producing immune-modulating
metabolites. However, microbes consume a variety of metabolites that may also impact host …
metabolites. However, microbes consume a variety of metabolites that may also impact host …
Setting “cold” tumors on fire: Cancer therapy with live tumor-targeting bacteria
Immunotherapy with checkpoint blockade has shown remarkable efficacy in many patients
with a variety of different types of cancer. However, the majority of patients with cancer have …
with a variety of different types of cancer. However, the majority of patients with cancer have …
Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model
H Yano, K Koga, T Sato, T Shinohara, S Iriguchi… - Cell Stem Cell, 2024 - cell.com
CD4+ T cells induced from human iPSCs (iCD4+ T cells) offer a therapeutic opportunity for
overcoming immune pathologies arising from hematopoietic stem cell transplantation …
overcoming immune pathologies arising from hematopoietic stem cell transplantation …
PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies
Tumor-infiltrating regulatory T cells (TI-Tregs) elicit immunosuppressive effects in the tumor
microenvironment (TME) leading to accelerated tumor growth and resistance to …
microenvironment (TME) leading to accelerated tumor growth and resistance to …
Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD …
T Sun, B Liu, L Cai, Y Zhou, W Yang, Y Li - Journal of Neuro-Oncology, 2024 - Springer
Purpose A strong immunosuppressive tumor microenvironment (TME) represents the major
barrier responsible for the failure of current immunotherapy approaches in treating …
barrier responsible for the failure of current immunotherapy approaches in treating …
Targeting intratumoral Tregs: The promise of CD25× TIGIT bispecific antibodies in solid tumor therapy
M Venkatachalapathy - Molecular Therapy, 2024 - cell.com
Cancer cells evade the immune system by activating immune checkpoint pathways to
suppress immune responses. In contrast, cancer immunotherapy has made remarkable …
suppress immune responses. In contrast, cancer immunotherapy has made remarkable …
[HTML][HTML] Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors
Homologous recombination deficiency (HRD) is prevalent in cancer, sensitizing tumor cells
to poly (ADP-ribose) polymerase (PARP) inhibition. However, the impact of HRD and related …
to poly (ADP-ribose) polymerase (PARP) inhibition. However, the impact of HRD and related …
Primary murine high-grade glioma cells derived from RCAS/tv-a diffuse glioma model reprogram naive T cells into immunosuppressive regulatory T lymphocytes
High-grade gliomas (HGGs) and glioblastomas (GBMs) are the most aggressive and lethal
brain tumors. The current standard of care (SOC) includes gross safe surgical resection …
brain tumors. The current standard of care (SOC) includes gross safe surgical resection …